Info on Orally Disintegrating Carbidopa-Levodopa

The U.S. Food and Drug Administration has approved orally disintegrating carbidopa-levodopa (Parcopa^®) for Parkinson's disease as well as Parkinson-like symptoms due to:

• Manganese poisoning
• Encephalitis
• Carbon monoxide poisoning.

These tablets are especially designed to dissolve rapidly on the tongue, without the need for water. This is particularly beneficial for people who have trouble swallowing tablets, which is often the case with Parkinson's disease. Prior to beginning treatment with this drug, review the drug's safety info with your healthcare provider. Orally disintegrating carbidopa-levodopa is not right for everyone. For example, those with malignant melanoma, a history of stomach or intestinal ulcers, or any lung problems may need to consider an alternative form of treatment. (Click Orally Disintegrating Carbidopa-Levodopa for more information on this drug, including how it works, possible side effects, what to do in cases of overdose, and more.)